Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1C3 | P42330 | 4/20 | 0.47 |
| ▸ | AKR1C2 | P52895 | 4/20 | 0.47 |
| ▸ | F2RL3 | Q96RI0 | 1/20 | 0.43 |
| ▸ | MBD2 | Q9UBB5 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 4/20 | 0.41 |
| ▸ | TP53 | P04637 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | ATM | Q13315 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.40 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.40 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.39 |
| ▸ | THRB | P10828 | 1/20 | 0.39 |
| ▸ | APP | P05067 | 1/20 | 0.39 |
| ▸ | PHGDH | O43175 | 1/20 | 0.39 |
| ▸ | CA12 | O43570 | 1/20 | 0.38 |
| ▸ | CA1 | P00915 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL72901 | 0.93 | AKR1C3 (0.47) | AKR1C3AKR1C2F2RL3MBD2LMNA | |
| SCHEMBL73436 | 0.82 | F2RL3 (0.46) | F2RL3MBD2LMNATP53MAPT | |
| SCHEMBL74474 | 0.80 | F2RL3 (0.42) | F2RL3MBD2LMNATP53MAPT | |
| SCHEMBL774164 | 0.79 | TP53 (0.57) | F2RL3MBD2LMNATP53MAPT | |
| Bromide SCHEMBL3863602 | 0.79 | LMNA (0.50) | F2RL3MBD2LMNATP53MAPT | |
| SCHEMBL14875121 | 0.79 | F2RL3 (0.46) | F2RL3MBD2LMNATP53MAPT | |
| SCHEMBL13539252 | 0.78 | LMNA (0.53) | F2RL3MBD2LMNATP53MAPT | |
| SCHEMBL73435 | 0.78 | FLT3 (0.52) | F2RL3MBD2LMNATP53MAPT | |
| SCHEMBL73916 | 0.77 | MBD2 (0.58) | F2RL3MBD2LMNATP53MAPT | |
| SCHEMBL29924814 | 0.76 | LMNA (0.49) | LMNATP53MAPTTSHRRAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8921546-B2 | Imidazolothiazole compounds for the treatment of disease | AMBIT BIOSCIENCES CORPORATION (US) | 2014-12-30 | — | — | US | disclosed |
| US-20140243525-A1 | IMIDAZOLOTHIAZOLE COMPOUNDS FOR THE TREATMENT OF DISEASE | AMBIT BIOSCIENCES CORPORATION (US) | 2014-08-28 | — | — | US | disclosed |
| US-8557810-B2 | Imidazolothiazole compounds for the treatment of disease | AMBIT BIOSCIENCES CORPORATION (US) | 2013-10-15 | — | — | US | disclosed |
| US-20120129850-A1 | IMIDAZOLOTHIAZOLE COMPOUNDS FOR THE TREATMENT OF DISEASE | AMBIT BIOSCIENCES CORPORATION | 2012-05-24 | — | — | US | disclosed |
| US-8129374-B2 | Method of using imidazolothiazole compounds for the treatment of disease | AMBIT BIOSCIENCE CORPORATION (US) | 2012-03-06 | — | — | US | disclosed |
| US-20070232604-A1 | receptor kinase inhibitors such as 3-(2-{4-[3-(5-tert-Butyl-isoxazol-3-yl)-ureido]-phenyl}-benzo[d]imidazo[2,1-b]thiazol-7-yl)-N-(2-morpholin-4-yl-ethyl)-propionamide; flk inhibitors | AMBIT BIOSCIENCES CORPORATION | 2007-10-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140243525-A1 | IMIDAZOLOTHIAZOLE COMPOUNDS FOR THE TREATMENT OF DISEASE | GRK2, GRK4, GRK3 | AKR1C3 3172/4885AKR1C2 2996/4885F2RL3 1215/4885 |
| US-20120129850-A1 | IMIDAZOLOTHIAZOLE COMPOUNDS FOR THE TREATMENT OF DISEASE | GRK2, GRK4, GRK3 | AKR1C3 3172/4885AKR1C2 2996/4885F2RL3 1215/4885 |
| US-20070232604-A1 | receptor kinase inhibitors such as 3-(2-{4-[3-(5-tert-Butyl-isoxazol-3-yl)-ureido]-phenyl}-benzo[d]imidazo[2,1-b]thiazol-7-yl)-N-(2-morpholin-4-yl-ethyl)-propionamide; flk inhibitors | GRK2, GRK3, BLK | AKR1C3 3419/4885AKR1C2 3028/4885F2RL3 414/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.